EMA starts reporting adverse events
Some could potentially be caused by a medicine, says the Agency
The European Medicines Agency (EMA) has released the first of regular documents highlighting potential safety concerns related to licensed medicines. These will note so-called ‘safety signals’ discussed at meetings of EMA’s pharmacovigilance risk assessment committee (PRAC). Such signals, said EMA, are 'information on a new or known adverse event that is potentially caused by a medicine and that warrants further investigation'.
EMA stressed that these may not prove that a medicine is to blame – problems could be caused by another illness or additional medicine. But they do need to be investigated to check a potential 'causal relationship between the medicine and the reported adverse event', said the Agency.